A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma


Full Title

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)


Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.

BMS-986458 breaks down a protein called BCL6 by binding to another protein called cereblon. BCL6 helps lymphoma cells survive and grow. By breaking down BCL6, BMS-986458 may slow lymphoma growth.

If you join this study, you will get BMS-986458 alone or with rituximab. BMS-986458 is taken orally (by mouth) and rituximab is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have NHL that came back or keeps growing even with treatment.
  • Have recovered from the serious side effects of treatment before getting the study therapy.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Jennifer Lue’s office at 646-608-4160.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID